What 12 Analyst Ratings Have To Say About Eli Lilly
Over the past 3 months, 12 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts…
Cowen & Co. Maintains Outperform on Eli Lilly, Raises Price Target to $430
Cowen & Co. analyst Steve Scala maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $390 to $430.
Nasdaq, S&P 500 Futures Nervously Flit Around Ahead Of November Payrolls Data: Will Numbers Support Market Expectations For Slower Rate Hikes?
US stocks are on track for a nervous start on Friday as traders look ahead to the November non-farm payrolls report for trading cues. With the Federal Reserve signaling its intention to potentially pivot, each incoming data is likely to trigger volatility in the market.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 108 stocks hit new 52-week highs.
Lilly Shares Donanemab Data In First Active Comparator Study In Early Symptomatic Alzheimer’s Disease; Says Met All Primary, Secondary Endpoints
Eli Lilly and Company (NYSE:LLY) has announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the Phase 3 TRAILBLAZER-ALZ 4 study, providing the first active comparator
Looking At Eli Lilly’s Recent Unusual Options Activity
Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Twitter Will Now Feature Gold, Gray, Blue Ticks: Elon Musk Details New Plan To Resolve Verification Mess
Elon Musk has floated a new plan to counter the negative impacts of the Twitter Blue verification that was rolled out briefly and then withdrawn.
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather disappointing."
The European average rate of receiving booster doses was only 29% in the groups considered to be at the highest risk.
Eli Lilly Unusual Options Activity For November 23
Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Berenberg Maintains Buy on Eli Lilly, Raises Price Target to $375
Berenberg analyst Kerry Holford maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $345 to $375.